Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
- Written by PR Newswire
 |
- Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health
- Data shows that 51% of participants achieved sustained unresponsiveness (clinical remission) to peanut after 18 months of treatment
- Prota Therapeutics announces new round of capital raising for further P3 clinical investigation and global commercialization...
